Core Viewpoint - The Shenzhen-Hong Kong Medical Index (983035) closed at 4488.12 points on November 25, with a 0.45% increase and a trading volume of 7.719 billion yuan, indicating a stable performance in the healthcare sector [1]. Group 1: Index Performance - On the same day, 40 out of the index's constituent stocks rose, with Ping An Good Doctor leading the gains at 4.27%, while 16 stocks declined, with Ruimaite leading the losses at 1.98% [1]. - The top ten constituent stocks of the Shenzhen-Hong Kong Medical Index include: - Mindray Medical (14.56% weight, market cap 235.068 billion yuan) [1] - Yier Eye Hospital (11.62% weight, market cap 108.081 billion yuan) [1] - Lejin Medical (4.85% weight, market cap 29.126 billion yuan) [1] - Aimeike (4.80% weight, market cap 44.039 billion yuan) [1] - Yuyue Medical (4.66% weight, market cap 35.758 billion yuan) [1] - Yingke Medical (3.64% weight, market cap 26.362 billion yuan) [1] - Furuishi (3.59% weight, market cap 17.422 billion yuan) [1] - Meinian Health (3.58% weight, market cap 21.215 billion yuan) [1] - China National Pharmaceutical (3.35% weight, market cap 57.888 billion yuan) [1] - Ping An Good Doctor (2.63% weight, market cap 28.822 billion yuan) [1]. Group 2: Capital Flow - The net outflow of main funds from the constituent stocks totaled 251 million yuan, while retail investors saw a net inflow of 199 million yuan [3]. - The detailed capital flow for selected stocks includes: - Aimeike: Main net inflow of 23.5405 million yuan, retail net outflow of 35.0461 million yuan [3]. - New Mileage: Main net inflow of 14.1523 million yuan, retail net outflow of 6.6983 million yuan [3]. - Jianfan Biological: Main net inflow of 4.5525 million yuan, retail net outflow of 8.5385 million yuan [3]. - A total of one stock was newly added to the Shenzhen-Hong Kong Medical Index in the last ten days [4].

证券代码：300015 证券简称：爱尔眼科 公告编号：2025-094 爱尔眼科医院集团股份有限公司 关于召开 2025 年第三次临时股东大会的提示性公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或 重大遗漏。 爱尔眼科医院集团股份有限公司（以下简称"公司"）于 2025 年 11 月 11 日在中国证 监会指定的信息披露网站巨潮资讯网（www.cninfo.com.cn）发布了《关于召开 2025 年第 三次临时股东大会的通知》，本次股东大会采用现场投票与网络投票相结合的方式召开， 现将有关事项提示如下： 一、召开会议的基本情况 1、股东会届次：2025 年第三次临时股东大会 2、股东会的召集人：董事会 3、本次会议的召集、召开符合《中华人民共和国公司法》《深圳证券交易所创业板股 票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号—创业板上市公司规范运作》 等法律、行政法规、部门规章、规范性文件及《公司章程》的有关规定。 4、会议时间： （1）现场会议时间：2025 年 11 月 27 日 14:30 （2）网络投票时间：通过深圳证券交易所系统进行网络投票的 ...

Core Insights - The establishment of the first "Difficult Lacrimal Disease Diagnosis and Treatment Center" by Aier Eye Hospital Group in Wuhan aims to provide specialized care for complex lacrimal diseases, leveraging multidisciplinary collaboration and precision treatment [1][2] - The center focuses on conditions such as lacrimal duct adhesion, chronic lacrimal duct rupture, and congenital absence of lacrimal ducts, addressing a significant healthcare need in Central China and nationwide [1] - Aier Eye Hospital plans to create a tiered diagnosis and treatment database for lacrimal diseases, standardizing treatment protocols and establishing a comprehensive service loop from diagnosis to rehabilitation [2] Summary by Sections Establishment and Purpose - Aier Eye Hospital Group has inaugurated its first center dedicated to difficult lacrimal diseases in Wuhan, which will serve as a model for future centers across the country [1] - The center aims to provide one-stop diagnostic and treatment services for patients suffering from complex lacrimal conditions [1] Medical Collaboration and Expertise - The center integrates experts from various fields, including lacrimal, nasal, and imaging specialties, to create a systematic multidisciplinary treatment approach [1] - The clinical challenges associated with complex lacrimal diseases often stem from trauma, inflammation, congenital abnormalities, or previous surgical failures, leading to low success rates in conventional surgeries [1] Future Plans and Community Support - Aier Eye Hospital intends to establish additional centers across the country, contributing to a national network for specialized lacrimal disease treatment [2] - The organization is also collaborating with the Eye Care Charity Foundation to provide financial assistance of up to 3,000 yuan for eligible patients, alleviating their economic burden and promoting eye health [2]

11 月 21 日，以 " 智领健康未来 " 为主题的 2025 华夏大健康产业发展暨康复服务大会在北京召开。作为连续四届引领行业风向的标杆盛会，科技与创新 始终是贯穿全程的灵魂主线，而医疗健康企业在环境、社会及治理方面的表现同样被社会各界关注。 万得 ESG高级分析师 受邀发表了主题演讲，详细介绍了蒲公英指数的构建背景、评估体系及市场表现，强调该指数为医疗健康行业可持续发展提供了重 要参考。 万得首先介绍了 Wind 万得的业务背景： "Wind 是一家专业化的信息服务机构，为金融领域开发了信息检索、数据提取及组合管理等专业工具，是国内外 机构投资者的重要合作伙伴。 " 她特别指出， Wind 构建的独立 ESG 评级体系已广泛应用于政策研究、金融决策和企业实践当中，例如国务院发展研究 中心发布的报告及可持续挂钩债券发行实践。 蒲公英指数亦是 Wind ESG 评级体系的一次创新性应用。该指数由华夏时报大健康研究院与万得联合研发，从医疗健康领域 A 股 495 家公司中精选前 50 家组成 " 蒲公英 50 指数 " ，港股 262 家公司中精选 30 家组成 " 蒲公英 30 指数 " ，每月根据 ESG ...

Core Insights - The International Retina Summit 100 (IRS100·2025) was held in Changsha, China, focusing on the theme "Focusing on Clinical, Integrating Innovation, Building Brightness Together" [1][2] - The event featured over 300 ophthalmology experts discussing cutting-edge technologies and solutions for retinal diseases, emphasizing global collaboration and innovation in the field [2][4] Group 1: Event Overview - IRS100·2025 included various forums covering topics such as gene therapy, artificial intelligence, surgical robotics, and stem cell research, showcasing the latest advancements in retinal medicine [1][2] - The summit aimed to enhance academic exchanges and promote the efficient translation of scientific achievements into clinical applications [4][6] Group 2: Key Contributions and Research - Notable experts presented significant research findings, including the identification of new pathogenic genes for familial exudative vitreoretinopathy (FEVR) and advancements in the treatment of retinoblastoma [10][12] - The summit highlighted the importance of early intervention in diabetic retinopathy and the potential of innovative treatment methods to improve patient outcomes [16][17] Group 3: Future Directions - The event underscored the need for international cooperation and foundational research breakthroughs to elevate the standard of care for retinal diseases [8][19] - The commitment to integrating AI, gene therapy, and robotic surgery into clinical practice was emphasized as a strategy to enhance personalized and precise solutions for complex retinal conditions [19][20]

Core Viewpoint - The importance of listed companies in stabilizing the capital market and promoting sustainable development is increasingly recognized, especially in the current environment where market sentiment is volatile. High-quality companies that focus on core operations and deliver excellent performance are essential to restore investor confidence and stabilize market expectations [1]. Group 1: Market Valuation and Investment Opportunities - A-share valuations are currently at a low level, indicating potential for recovery and highlighting long-term investment value [2][3]. - The medical industry is expected to grow significantly due to China's large population and increasing healthcare demands, driven by the "Healthy China" strategy [2]. - The market is experiencing a divergence where funds are increasingly concentrated on high-quality companies, reflecting a shift towards value investing [4][5]. Group 2: Company Actions and Strategies - Companies like Aier Eye Hospital are committed to aligning interests with investors and enhancing performance, achieving a market value of approximately 80 billion yuan, which is 12 times its initial listing value [6]. - Dabeinong is balancing short-term and long-term goals through employee stock ownership plans to ensure sustainable growth [6]. - Guolinda aims for stable revenue growth and successful cloud transformation while focusing on shareholder returns [7]. Group 3: Economic Environment and Future Outlook - Positive fiscal policies are anticipated in the second half of the year, which may improve the macroeconomic environment and boost investor confidence [3]. - The A-share market is expected to gradually return to value investing as macro policies adjust and market sentiment stabilizes [2][3]. - The inclusion of A-shares in the MSCI index is seen as a beneficial factor, indicating a potential shift in market investment styles towards high-quality growth companies [4].

Core Viewpoint - The company, Aier Eye Hospital, addressed investor inquiries regarding its optical services, tax policies, and financial practices, emphasizing transparency and adherence to regulations [1]. Financial Practices - Aier Eye Hospital confirmed that it follows a unified accounting policy across its subsidiaries and adheres to the "Basic Norms for Internal Control of Enterprises" [1]. - The company conducts self-assessments and supervision of its internal controls and hires independent accounting firms annually to audit its financial report controls [1]. Tax Policies - The company indicated that details regarding its business accounting and tax policies are disclosed in its annual and interim reports, inviting investors to review these documents for comprehensive information [1]. Medical Services - Aier Eye Hospital acknowledged the inquiries about its compliance with medical service pricing regulations and the specific medical services it offers that meet insurance and tax requirements, although specific services were not detailed in the response [1].

Core Viewpoint - The 2025 Huaxia Health Industry Development and Rehabilitation Service Conference emphasizes the importance of technology and innovation in the healthcare sector, alongside the growing focus on environmental, social, and governance (ESG) performance of healthcare companies [2][3]. Group 1: ESG Rating System - The Dandelion Index, developed by Huaxia Times Health Research Institute and Wind, selects the top 50 companies from 495 A-share healthcare companies and 30 from 262 Hong Kong healthcare companies, adjusting the components monthly based on ESG scores [3][4]. - The ESG rating system evaluates companies on long-term management practices across environmental, social, and governance dimensions, incorporating over 500 indicators and 28 topics, with a focus on industry-specific issues [4][7]. Group 2: Index Performance - The Dandelion Index shows superior performance, with the Dandelion 50 Index rising approximately 29% year-to-date, outperforming the CSI 300 and healthcare industry indices by about 35 percentage points, with an annualized return of around 10% [8][11]. - The Dandelion 30 Index has achieved a year-to-date increase of 104%, significantly surpassing the Hong Kong healthcare industry index and the Hang Seng Index, with a five-year cumulative return of 63% [11][12]. Group 3: Company Ratings - 80 companies with excellent ESG performance are included in the Dandelion Index, with Haier Biomedical and Yinkang Life receiving the highest AAA rating [7]. - In the Dandelion 50 Index, 62% of companies are rated AA, while 34% are rated A; the Dandelion 30 Index has 77% rated AA, with no low-rated companies, contrasting with over 69% of the healthcare industry having low ratings [7][8]. Group 4: Call to Action - The conference encourages more companies to engage in ESG practices and register on the Wind ESG issuer communication platform for rating feedback, aiming to promote sustainable development in the industry [14].

Core Insights - Aier Eye Hospital has been awarded the "2025 Empowering a Better Life Case" award for its exceptional brand building, continuous technological innovation, social responsibility, and high-quality service [2] - The company has established a comprehensive medical education and research integration platform, ensuring a full talent cultivation chain from undergraduate to doctoral levels, which supports its sustainable development and injects vitality into the ophthalmology industry [3] - Aier Eye Hospital is leveraging AI technology to reshape eye health services through a "five-in-one" layout, significantly enhancing its technological capabilities and transforming the service paradigm in ophthalmology [4] - The company has actively engaged in social responsibility initiatives, participating in 873 public welfare projects across 31 provinces and regions in China, and has been recognized with the "China Charity Award" for three consecutive years [4] - Aier Eye Hospital is committed to its mission of ensuring eye health rights for all, regardless of socioeconomic status, and aims to continuously innovate in medical technology and improve service quality [5] Company Strategy - The company focuses on a global development ecosystem in five key areas: medical services, talent cultivation, scientific research, industrial collaboration, and investment layout [2] - Aier Eye Hospital has established international clinical diagnosis and training centers, promoting advancements in ophthalmology and providing precise and efficient treatment options for patients [3] - The integration of AI in its operations aims to enhance the intelligence and warmth of medical services, reflecting the ultimate value of technological innovation [4] Social Responsibility - Aier Eye Hospital's sustainable public welfare model has received high recognition from various sectors, demonstrating its commitment to social responsibility [4] - The company aims to provide high-quality and convenient eye health services while contributing to the construction of a healthy China and safeguarding public eye health [5]

Market Overview - The medical services sector experienced a decline of 2.71% on November 21, with Baihua Pharmaceutical leading the drop [1] - The Shanghai Composite Index closed at 3834.89, down 2.45%, while the Shenzhen Component Index closed at 12538.07, down 3.41% [1] Stock Performance - Notable gainers included Yangguang Nuohua, which rose by 4.47% to a closing price of 61.21, with a trading volume of 86,300 shares and a transaction value of 530 million [1] - Baihua Pharmaceutical saw a significant decline of 9.67%, closing at 9.06, with a trading volume of 292,400 shares and a transaction value of 275 million [2] - Other notable decliners included Chengda Pharmaceutical (-9.58%), Berry Genomics (-8.67%), and Guangzheng Eye Hospital (-7.26%) [2] Capital Flow - The medical services sector experienced a net outflow of 1.325 billion in institutional funds, while retail investors saw a net inflow of 1.332 billion [2] - The table of capital flow indicates that major stocks like Yangguang Nuohua had a net inflow of 10.986 million from institutional investors, while retail investors had a net inflow of 1.374 million [3]